These data highlight the potential of <i>MYD88</i><sup>L265P</sup> mutation-specific peptide-based immunotherapy as a novel personalized treatment approach for patients with <i>MYD88</i><sup>L265P+</sup> NHLs that may complement pharmacological approaches targeting oncogenic MyD88 L265P signaling.
We identified the MYD88 L265P somatic variant in cases with WM (39/42), MGUS (8/18), NHL (14/41, including 4/13 diffuse large B cell lymphoma (DLBCL), 1/8 mucosa-associated lymphoid tissue, 3/6 splenic marginal zone lymphoma (SMZL), 1/4 chronic lymphocytic leukemia, 2/3 nodal marginal zone lymphoma (NMZL), 1/2 mantle cell lymphoma, 1 Burkitt lymphoma, and 1 B cell NHL that could not be classified), primary AL (2/2), and IgM-PN (1/1).